

10/634,709

18

PC25236A

REMARKS

Claims 12, 14, and 16 to 28 are pending in the application.

Claims 22 and 26 to 28 are currently amended.

Claims 12, 14, 16 to 20, and 23 to 25 were previously presented.

Claim 21 is canceled.

Claims 12, 14, 16 to 20, and 22 to 28 would be all of the claims pending in the application if the present amendment is entered.

Claim 22 had depended from claim 21, now canceled. So claim 22 is currently amended and now recites all of the subject matter that was previously incorporated from claim 21 except for the definition of the term 5-membered heteroarylenyl, which term is not recited in claim 22. Claims 26 to 28 are amended to depend from claim 22 instead of claim 21.

Claim Rejections – 35 U.S.C. § 103

In the Office Action, claim 21 is rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Riordan et al., U.S. Patent No. 5,756,524. It was stated in the Office Action that the Riordan et al. patent teaches several anilide derivatives as fungicides, and that these derivatives include compounds in the instant claim[s].

Without acquiescing to this rejection, Applicants have canceled claim 21, rendering the rejection moot. Applicants have canceled claim 21 to advance prosecution of the remaining claims, which are either allowed or would be allowable for the reason mentioned below.

Allowable Subject Matter

In the Office Action, claims 12, 14, and 16-20 are allowed and claims 22-28 are objected to as being dependent upon a rejected base claim 21, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim 21 is canceled and claim 22 is rewritten in independent form with all of the limitations of claim 21 except for the definition of the term 5-membered heteroarylenyl. The dependencies of claims 26-28 are amended. Claims 22-28 no longer depend from

10/634,709

19

PC25236A

claim 21. Accordingly, Applicants believe that claims 22-28 are now in condition for allowance.

Conclusion

Applicants note that in the Office Action, claims 12, 14, and 16-20 are allowed. In view of the above remarks, Applicants believe that the rejection is overcome and request reconsideration of claims 22-28 and a Notice of Allowance for claims 12, 14, 16-20, and 22-28.

Respectfully submitted,

Date: August 24, 2006

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.
Reg. No. 47,871
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553